ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
Scientists in Switzerland may have found a way to inhibit the growth of colon cancer in humans, says a new study published in EMBO Molecular Medicine.